Generate Biomedicines is a clinical-stage biotech that uses generative AI to design novel protein therapeutics. The company's core asset is its Generate Platform, which combines AI-based generative models with high-throughput lab hardware to design protein drug candidates. Generate argues this approach produces higher-quality candidates faster than traditional drug discovery. Generate's lead product candidate is GB-0895, an anti-TSLP monoclonal antibody designed for twice-yearly dosing in severe asthma. Existing approved biologics for severe asthma require dosing every two to eight weeks, and Generate designed GB-0895 with ultra-high binding affinity and an extended half-life to enable the less frequent schedule. GB-0895 is currently enrolling patients in two Phase 3 trials. Generate also has two oncology candidates entering Phase 1 in 2026: GB-4362, an antibody designed to neutralize the toxic payload released by certain cancer drugs to reduce side effects, and GB-5267, a CAR-T cell therapy for ovarian cancer developed with Roswell Park. Generate has two revenue streams: collaboration revenue from licensing its platform to pharma partners, and an internal pipeline it intends to commercialize independently. Its primary partners are Amgen and Novartis, each of which paid $50M upfront. Generate was founded in 2018 by Flagship Pioneering, which remains the dominant shareholder, and is led by CEO Michael Nally, formerly of Merck.